Back to first-pass browser

First-pass extracted concept

ovarian cancer

Candidate: concept label1 source documents9 linked claims
Jump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

OV

Evidence Snippets

In this study, we systematically investigated the expression pattern, prognostic relevance and functional impact of SNX1 in OV.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1drug interactionsupports2026Source 1DOIPubMed

SNX1 overexpression shows a synergistic anti-tumor effect with paclitaxel treatment in ovarian cancer drug sensitivity analysis.

Claim 2expression associationsupports2026Source 1DOIPubMed

SNX1 is significantly downregulated in ovarian cancer tissues.

Claim 3functional effectsupports2026Source 1DOIPubMed

SNX1 overexpression inhibits ovarian cancer cell proliferation and blocks G1/S transition.

Claim 4functional effectsupports2026Source 1DOIPubMed

SNX1 overexpression promotes apoptosis in ovarian cancer cells.

Claim 5migration effectsupports2026Source 1DOIPubMed

SNX1 overexpression suppresses ovarian cancer cell migration and shifts EMT markers toward an epithelial state, with increased E-cadherin and decreased N-cadherin, vimentin, Snail1, and beta-catenin.

Claim 6molecular effectsupports2026Source 1DOIPubMed

SNX1 overexpression is associated with downregulation of E2F1, CDK2, CDK6, and cyclin D1 during G1/S blockade in ovarian cancer cells.

Claim 7pathway associationsupports2026Source 1DOIPubMed

SNX1 downregulation in ovarian cancer is linked by gene set enrichment analysis to activation of p53 signaling, PI3K/AKT signaling, E2F targets, and G2/M checkpoint programs.

Claim 8prognostic associationsupports2026Source 1DOIPubMed

Low SNX1 expression is associated with poor overall and progression-free survival in ovarian cancer.

Claim 9role assignmentsupports2026Source 1DOIPubMed

SNX1 acts as a tumor suppressor and potential therapeutic target in ovarian cancer.